Insider Selling: Nautilus Biotechnology, Inc. (NASDAQ:NAUT) VP Sells 35,000 Shares of Stock

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) VP Mary E. Godwin sold 35,000 shares of the company’s stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $2.85, for a total transaction of $99,750.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Nautilus Biotechnology Stock Up 2.7 %

Shares of NAUT opened at $3.08 on Friday. Nautilus Biotechnology, Inc. has a 52-week low of $2.19 and a 52-week high of $3.62. The firm has a market capitalization of $385.82 million, a PE ratio of -5.60 and a beta of 1.20. The firm has a 50-day moving average price of $2.59 and a 200 day moving average price of $2.59.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its quarterly earnings data on Tuesday, July 30th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.02. During the same quarter last year, the business posted ($0.13) EPS. On average, equities analysts expect that Nautilus Biotechnology, Inc. will post -0.65 EPS for the current year.

Institutional Investors Weigh In On Nautilus Biotechnology

A number of institutional investors and hedge funds have recently bought and sold shares of NAUT. Price T Rowe Associates Inc. MD raised its holdings in shares of Nautilus Biotechnology by 35.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 16,078 shares of the company’s stock worth $48,000 after purchasing an additional 4,239 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Nautilus Biotechnology by 66.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 24,076 shares of the company’s stock worth $71,000 after acquiring an additional 9,624 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Nautilus Biotechnology by 11.2% in the 2nd quarter. Renaissance Technologies LLC now owns 140,100 shares of the company’s stock worth $328,000 after acquiring an additional 14,100 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Nautilus Biotechnology by 19.8% during the second quarter. Dimensional Fund Advisors LP now owns 574,844 shares of the company’s stock valued at $1,345,000 after purchasing an additional 94,908 shares during the last quarter. Finally, Clarius Group LLC lifted its holdings in shares of Nautilus Biotechnology by 2.7% during the second quarter. Clarius Group LLC now owns 636,532 shares of the company’s stock valued at $1,489,000 after purchasing an additional 16,661 shares during the last quarter. 50.71% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have commented on NAUT shares. Guggenheim started coverage on shares of Nautilus Biotechnology in a research report on Thursday, June 27th. They issued a “buy” rating and a $6.00 target price for the company. Jefferies Financial Group started coverage on Nautilus Biotechnology in a research report on Monday, June 3rd. They issued a “hold” rating and a $3.00 target price on the stock.

About Nautilus Biotechnology

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.